Daiichi Sankyo is a global pharmaceutical company engaged in the research and development, manufacturing, and sale and marketing of innovative and generic drugs, vaccines, and over-the counter medicines.
Daiichi Sankyo has an active licensing and acquisition group charged with analysing and managing all incoming opportunities. Daiichi Sankyo has a long history of partnering, building numerous collaborative partnerships.
Like many companies, Daiichi Sankyo seeks to be ‘partner of choice’ in its target therapy and technology areas. The company seeks collaboration with academia and venture companies in Japan and overseas.
To expand its business, the company is keen on partnering on promising products that complement its in-house portfolio and will help it achieve long-term growth.
Daiichi Sankyo’s strategy involves acquiring new products and product candidates, and companies that will drive our portfolio in key therapeutic areas. The companiy’s decades-long history of effective collaboration exemplifies its ability to license products in and out of Daiichi Sankyo, develop and maintain valuable partnerships, and successfully complete mergers and acquisitions.
Daiichi Sankyo partnering process
Daiichi Sankyo’s Business Development and Licensing team’s mission is to expand the business by partnering on high potential products that complement in-house portfolio (therapeutically, and by stage of development).
Daiichi Sankyo’s experience is that most of the value generated by alliances takes shape after the conclusion of contracts. As a result, the company attach great importance to bolstering its alliance management capabilities with an eye to maximizing that value.
Here’s how Daiichi Sankyo accomplishes itsvision for success:
- Acquire new product candidates, new products and/or companies that will drive our portfolio in key therapeutic categories. We use our world-class scientific capabilities to continually innovate and improve our R&D processes for medicines in fields such as:
- Cardiovascular and Metabolic Disorders
- "Frontier" — innovative discoveries in a variety of mechanisms and diseases
- Establish sustainable partnerships through open and fair alliance management:
- Provide balanced support to serve the interests of the alliance
- Learn from partners to improve competencies and develop best practices
Summary of Daiichi Sankyo partnering interests
To fulfill its mission of contributing to the enrichment of quality of life worldwide through the creation and provision of innovative pharmaceuticals addressing diverse medical needs, Daiichi Sankyo continue to seek partners that match its values, work ethic and commitment to patients.
Daiichi Sankyo focus areas for in-licensing are:
- Cardiovascular and Metabolic Disorders
- Type 2 diabetes and Beta-cell function
- Dyslipidemia and stroke
- Cardiac and kidney dysfunction
- Obesity and peripheral vascular disease
- Pathways implicated in oncogene addiction or therapeutic resistance
- Novel epigenetic or cancer stem cell targets
- Agents synergizing with our existing oncology pipeline
- Novel mechanisms of action (MOAs) that address significant unmet needs
- Late-stage/marketed products requiring strong commercial execution
For the latest detail on Daiichi Sankyo partnering interests, visit the partnering section of Daiichi Sankyo website > go to About us > Partnerships for details.
Daiichi Sankyo are routinely present at a large number of partnering events throughout the year.
Partnering events are a great place to meet lots of potential partners face to face in a small amount of time.
Events with Daiichi Sankyo presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Daiichi Sankyo in person visit Current Partnering’s Event calendar.
Contacting Daiichi Sankyo for partnering
Daiichi Sankyo can be contacting in relation to partnering through a number of channels.
Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
Direct contact: there are several sources of direct contact with Daiichi Sankyo business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel. Many of Daiichi Sankyo business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Daiichi Sankyo LinkedIn page here.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. Daiichi Sankyo provides an online opportunity submission form which can be found by visiting Daiichi Sankyo website > go to About us > Partnerships for details.
Available reports from Current Partnering
Report: Partnering Agreements with Daiichi Sankyo 2005-2013
Available resources for deal coverage for Daiichi Sankyo
Read: more on Daiichi Sankyo company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk